Drug Search Results
More Filters [+]

Artemisinin

Alternative Names: artemisinin, coartem
Latest Update: 2024-12-03
Latest Update Note: News Article

Product Description

Artemisinins are derived from extracts of sweet wormwood (Artemisia annua) and are well established for the treatment of malaria, including highly drug-resistant strains. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758403/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Brazil | China | Colombia | Dominican Republic | Indonesia | Pakistan | Peru | South Africa | Thailand | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Artemisinin

Countries in Clinic: China, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Cervical Cancer|Papillomavirus Infections|Uterine Cancer|Uterine Cervical Dysplasia

Phase 1: Malaria, Falciparum|Malaria, Vivax

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ART-CIN_IIB

P2

Recruiting

Uterine Cervical Dysplasia|Uterine Cancer|Papillomavirus Infections|Cervical Cancer

2025-07-31

CTR20242902

P1

Recruiting

Malaria, Vivax|Malaria, Falciparum

None

Recent News Events